New drug offers hope for children with extreme hunger due to brain damage

A groundbreaking treatment, the drug setmelanotide, shows significant promise for children and adults suffering from extreme hunger and severe obesity caused by brain damage, particularly following brain tumors. This rare but life-threatening condition, known as hypothalamic obesity, affects an estimated 150 children and 500 adults in the Netherlands. The damage to the hypothalamus, a brain region regulating appetite and metabolism, leads to uncontrollable hunger and inefficient fat conversion, resulting in morbid obesity. Traditional methods like diet and exercise have proven ineffective as they do not address the underlying brain damage.

International research published in The New England Journal of Medicine, involving 120 participants from six countries including the Netherlands, demonstrated remarkable results. Patients treated with setmelanotide experienced substantial weight loss, with their Body Mass Index (BMI) decreasing by an average of 16.5 percent within a year. In contrast, those receiving a placebo saw their BMI increase by 3.3 percent. Pediatrician Hanneke van Santen, who led the Dutch arm of the study, described the findings as a breakthrough, noting that patients continuing the medication appear to be returning to normal weights.

The drug's effectiveness extends beyond physical health, with young patients showing significant mental and emotional improvements. The severe impact of hypothalamic obesity disrupts family life, creating untenable situations due to the child's uncontrolled hunger and reduced impulse control. Following these convincing results, regulatory agencies in Europe and the United States have approved setmelanotide. Discussions are underway regarding its availability and reimbursement in the Netherlands, with hopes for swift access for affected patients.